0001104659-20-072779.txt : 20200714 0001104659-20-072779.hdr.sgml : 20200714 20200612134243 ACCESSION NUMBER: 0001104659-20-072779 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD

SUITE 220

HAMPTON NJ 08827

 

June 12, 2020

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

  Re: Celldex Therapeutics, Inc. (the “Company”)

 

Registration Statement on Form S-3, as amended (File No. 333-235399)

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 2:00p.m., Eastern Time, on June 12, 2020, or as soon as practicable thereafter.

 

Please call Anthony O. Pergola of Lowenstein Sandler LLP at 212.204.8689 to confirm the effectiveness of the Registration Statement or with any questions.

 

[Signature page follows.]

 

 

 

 

U.S. Securities and Exchange Commission

June 12, 2020

Page 2

 

  Very truly yours,
  CELLDEX THERAPEUTICS, INC.
   
  By: /s/ Sam Martin
  Name: Sam Martin
  Title: Senior Vice President, Chief Financial
    Officer and Treasurer

 

- 2 -